Skip to main content
Lyka Labs Ltd. logo

Lyka Labs Ltd. — Investor Relations & Filings

Ticker · LYKALABS ISIN · INE933A01014 LEI · 3358001RHQJBCTT1ER45 BSE.NS Manufacturing
Open in API
Filings indexed 1,205 across all filing types
Latest filing 2019-03-30 Regulatory Filings
Country IN India
Listing BSE.NS LYKALABS

About Lyka Labs Ltd.

https://www.lykalabs.com

Lyka Labs Ltd. specializes in the development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company maintains a diverse product portfolio spanning multiple therapeutic categories, including anti-infectives, dermatologicals, cardiovascular agents, and pain management. A significant area of expertise for the organization is lyophilization technology, enabling the production of high-quality injectable formulations. The company operates advanced manufacturing facilities designed to meet international quality standards, supporting its operations in both domestic and global markets. Its core activities encompass the production of various dosage forms such as tablets, capsules, ointments, and sterile injectables, with a particular focus on specialized segments like cephalosporins and critical care medications.

Recent filings

Filing Released Lang Actions
Pursuant to regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Company's account was classified as Non-Performing ....
Regulatory Filings
2019-03-30 English
Pursuant to regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the information regarding loss/misplacement of share certificate ....
Regulatory Filings
2019-03-26 English
Outcome of Board Meeting
Regulatory Filings
2019-02-13 English
Financial Result Updates
Regulatory Filings
2019-02-12 English
Board Meeting — Financial Results
Regulatory Filings Classification · 100% confidence The document text contains only a placeholder for a picture and no substantive content. The true document length is only 55 characters, indicating it is extremely short and contains no report or detailed information. Given the lack of content, this cannot be classified as any detailed report or announcement. It fits best as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings with no specific content.
2019-02-05 English
Updates
Regulatory Filings Classification · 95% confidence The document is very short (488 characters) and appears to be a formal communication addressed to stock exchanges (Bombay Stock Exchange and National Stock Exchange of India) with script codes mentioned. There is no substantive financial data, no report content, no discussion of financial results, or any detailed information. It looks like a brief letter or notice, possibly related to regulatory or listing matters. Given the brevity and nature, it does not qualify as a full report or detailed announcement. It fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous filings that do not fit other specific categories.
2019-01-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.